Bryan, Garnier & Co's News

Ablynx: Pharmas lining up around the block

BUY vs. CORPORATE, Fair Value EUR17 vs. EUR16 (+42%)
News published on
October Tuesday 27, 2015


Full report released today


Ablynx has a promising maturing pipeline built on a breakthrough technology platform, Nanobodies, which has the potential to overcome the limitations of conventional antibodies and to be positioned as a first-class asset in a buoyant market (rheumatoid arthritis and immuno-oncology among others). Already backed by leading pharmaceutical companies through partnership agreements across multiple therapeutic areas, Ablynx also has a proprietary late stage pipeline that could enable it to evolve its business model towards a vertical integrated biopharmaceutical company.


For more information, please contact marketing@bryangarnier.com